Genmab: Arzerra 2Q Net Sales DKK73M

21st Jul 2010 12:10

DOW JONES NEWSWIRES Genmab Wednesday said net sales of Arzerra for the second quarter of 2010 were approximately DKK73 million, with an expected royalty payment to Genmab of approximately DKK15 million. MAIN FACTS: -2Q net sales in the U.S. approximately DKK64 million. -2Q rest of the world sales approximately DKK9 million. -Arzerra was granted accelerated approval by the FDA in Oct. 2009, for the treatment of patients in the U.S. with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. -Arzerra was launched by GSK in mid-Nov. 2009. -EU conditional marketing approval granted in April 2010. -By Stockholm Bureau, Dow Jones Newswires; +46-8-5451-3090; [email protected] (END) Dow Jones Newswires July 21, 2010 07:10 ET (11:10 GMT)